| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.sanjivani.co.in | |
| Market Cap | 207.92 Cr. | |
| Enterprise Value(EV) | 208.61 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 5.05 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 35.23 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 40.73 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 21.06 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 8.45 | Calculated using Price: 177.95 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 1.17 Cr. | 11,684,300 Shares |
| FaceValue | 10 | |
| About Sanjivani Paranteral Ltd. | ||
| Sanjivani Parenteral was established in 1997 by A H Khemka, Ashwin Khemka and Somesh Khemka, under the technical direction of Mahendra Kalwankar. It is a research-based, international pharmaceutical company that provides a wide range of high quality products and services at affordable prices. The core product range of the company's products includes oral solids, small volume parenterals and sterile powder formulations. | ||
| 1 Day |
|
+6.17% |
| 1 Week |
|
+20.21% |
| 1 Month |
|
+33.53% |
| 3 Month |
|
+9.18% |
| 6 Month |
|
+35.30% |
| 1 Year |
|
+328.43% |
| 2 Year |
|
+192.01% |
| 5 Year |
|
+5243.28% |
| 10 Year |
|
+1058.58% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | -7.19 | -58.98 | -596.93 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Return on Capital Employed (%) | 5.69 | -7.28 | -33.04 | -227.28 | 0 | -265.98 | 266.43 | 0 | 0 | |
| Return on Assets (%) | -2.09 | -14.16 | -34.18 | -124.34 | -9.62 | -10.16 | 8.13 | 25.8 | 22.96 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 32 | 18 | -9 | -53 | -47 | -49 | -45 | -8 | -3 | 0 | |
| Non Curr. Liab. | 7 | 14 | 9 | 6 | 10 | 9 | 7 | 4 | 1 | 1 | |
| Curr. Liab. | 75 | 62 | 61 | 72 | 56 | 55 | 58 | 22 | 23 | 23 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 114 | 93 | 60 | 25 | 18 | 16 | 19 | 18 | 21 | 24 | |
| Non Curr. Assets | 16 | 23 | 17 | 16 | 11 | 12 | 10 | 11 | 13 | 11 | |
| Curr. Assets | 98 | 70 | 43 | 9 | 7 | 4 | 9 | 8 | 8 | 14 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 114 | 93 | 60 | 25 | 18 | 16 | 19 | 18 | 21 | 24 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 133 | 115 | 33 | 18 | 25 | 16 | 25 | 31 | 35 | 50 | |
| Other Income | 1 | 1 | 3 | 0 | 1 | 0 | 0 | 2 | 1 | 0 | |
| Total Income | 135 | 116 | 36 | 18 | 26 | 17 | 25 | 32 | 36 | 50 | |
| Total Expenditure | -128 | -121 | -56 | -70 | -27 | -17 | -23 | -26 | -30 | -42 | |
| PBIDT | 7 | -5 | -20 | -52 | -1 | 0 | 2 | 6 | 6 | 8 | |
| Interest | -8 | -9 | -5 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | |
| Exceptional Items | 0 | ||||||||||
| PAT | -2 | -15 | -26 | -53 | -2 | -2 | 1 | 5 | 5 | 6 | |
| Adjusted EPS | -4 | -25 | -44 | -90 | -4 | -3 | 2 | 5 | 5 | 6 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 9 | -1 | 0 | 10 | 3 | 2 | 0 | 1 | 9 | 5 | |
| Cash Fr. Inv. | -1 | 9 | -1 | 0 | 0 | 0 | 0 | 0 | -1 | -1 | |
| Cash Fr. Finan. | -8 | -7 | -1 | -10 | -3 | -2 | 0 | 0 | -8 | -4 | |
| Net Change | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cash & Cash Eqvt | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Tue, 16 Apr 2024
Compliance Certificate- Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Compliance Certificate as per regulation 7(3) of SEBI (LODR) Regulations 2015 for the period ended 31st March 2024 |
|
Fri, 12 Apr 2024
Compliance Certificate As Per Regulation 40(9) Of SEBI (LODR) Regulations 2015 For The Period 01St April 2023 To 31St March 2024 Compliance Certificate as per Regulation 40(9) of SEBI (LODR) Regulation 2015 for the period 01st April 2023 to 31st March 2024 |
|
Fri, 12 Apr 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificated under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the period 01st January 2024 to 31st March 2024. |
| Fri, 19 Apr 2024 |
High Delivery Percentage
|
Higher Delivery Quantity
|
Higher Delivery Quantity and Percentage
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
